Shares of Drugs Made in America Acquisition Corp. (NASDAQ:DMAAU – Get Free Report) were up 0.4% on Tuesday . The stock traded as high as $10.17 and last traded at $10.17. Approximately 451 shares were traded during trading, a decline of 100% from the average daily volume of 104,418 shares. The stock had previously closed at $10.13.
Drugs Made in America Acquisition Price Performance
The stock has a fifty day moving average price of $10.09.
Drugs Made in America Acquisition Company Profile
Drugs Made In America Acquisition Corp. is a blank check company newly incorporated in the Cayman Islands as an exempted company incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.
See Also
- Five stocks we like better than Drugs Made in America Acquisition
- Financial Services Stocks Investing
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- 3 REITs to Buy and Hold for the Long Term
- Top 3 Beverage Stocks Pouring Out Profits
- Top Stocks Investing in 5G Technology
- CarMax and Carvana: Steering the Used Car Market
Receive News & Ratings for Drugs Made in America Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Drugs Made in America Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
